MRSA
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a form of contagious bacterial infection. People sometimes call it a superbug because it is resistant to numerous antibiotics. In healthy people, MRSA does not usually cause a severe infection, but older people, individuals with health conditions, and those with a weakened immune system may be at risk. MRSA is a common and potentially serious infection that has developed resistance to several types of antibiotics. These include methicillin and related antibiotics, such as Penicillin, Vancomycin, and Oxacillin. This resistance makes MRSA difficult to treat.
Most MRSA infections occur in people who've been in hospitals or other health care settings, such as nursing homes and dialysis centers. When it occurs in these settings, it's known as health care-associated MRSA (HA-MRSA). HA-MRSA infections typically are associated with invasive procedures or devices, such as surgeries, intravenous tubing or artificial joints. Another type of MRSA infection has occurred in the wider community among healthy people. This form, community-associated MRSA (CA-MRSA), often begins as a painful skin boil. It's spread by skin-to-skin contact.
Related Conference of MRSA
5th International conference on Vaccines, Vaccination and Immunization
19th International Conference on Allergy and Clinical Immunology
5th International Conference on Immunology And Immunotherapy
MRSA Conference Speakers
Recommended Sessions
- Adverse Drug Reactions
- Antibiotic Prophylaxis
- Antibiotic Regulatory Affairs
- Antibiotic Resistance: Opportunities and Challenges
- Antibiotics
- Antibiotics and Mechanism of Action
- Antibiotics for Emerging and Re-emerging Diseases
- Antibiotics for Various Diseases and Infections
- Antibiotics in Different Industries
- Antibiotics: In Pregnancy and Lactation
- Antibiotics: Market Analysis and Business Opportunities
- Antimicrobial Peptides
- Antimicrobial Therapy
- Applications of Antibiotics
- Bio Chemical Pharmacology
- Clinical Pharmacy and Pharmacotherapeutics
- Clinical Research Statistics
- Clinical Trials of Antibiotics
- Current Research in Antibiotic Resistance
- Developing Alternatives to Antibiotics
- Different Types of Antibiotics
- Drug Discovery and Novel Delivery Technologies
- Drug Safety Testing
- Drug Screening and Discovery
- Micro Organisms in Recent Drug Discovery
- MRSA
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs
- Pharmacology
- Pre-clinical and Clinical Trails
- Prevention and Control of Antibiotic Resistance
- The Emergence of Antimicrobial Resistance
- The Next Generation Approach of Antibiotics
- Toxicology
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)